Effective August 1, 2026, Louisiana Act 374 limits certain licensing board restrictions involving peptide prescribing, compounding, and dispensing when applicable state and federal requirements are met.
Limits on Licensing Board Restrictions for Compliant Peptide Prescribing and Compounding
On August 1, 2026, Louisiana Act 374 took effect to limit certain restrictions that professional and occupational licensing boards may place on peptide prescribing, compounding, and dispensing. For Med Spa operators offering peptide-related services, the law establishes new limits on board authority while maintaining applicable state and federal requirements.
Key Details in Louisiana Act 374 for Peptide Prescribing, Compounding, and Dispensing
Louisiana Act 374 originated as Senate Bill 253 during the 2026 Regular Session and was signed by Governor Jeff Landry on May 22, 2026. Effective August 1, 2026, the law added R.S. 37:23.5, which addresses limits on how professional and occupational licensing boards may regulate certain peptide-related activities.
Under the law, licensing boards may not prohibit a healthcare provider with prescriptive authority from providing patients with peptides when the statutory conditions are met.
This applies to peptides obtained through either of the following sources:
- An FDA-registered 503B outsourcing facility that complies with 21 U.S.C. § 353b.
- A 503A compounding pharmacy that complies with 21 U.S.C. § 353a and applicable United States Pharmacopeia–National Formulary (USP–NF) chapters.
Act 374 separately addresses Louisiana-licensed pharmacists practicing within state-permitted pharmacies. Licensing boards may also not prohibit these pharmacists from compounding and dispensing peptides when the pharmacist and pharmacy comply with the federal 503A requirements and applicable USP–NF chapters.
As of this reporting, Act 374 addresses the regulation of peptides by Louisiana professional and occupational licensing boards, including circumstances involving authorized healthcare providers and compounding pharmacies. The law does not grant new prescriptive authority or replace the federal compounding standards referenced in its provisions.
Source Attribution and Legislative Record
According to the Louisiana Legislature, Act 374 was enacted during the 2026 Regular Session to address licensing board regulation of peptides and became effective August 1, 2026.
Existing Peptide Compliance Considerations Under Act 374 and FDA Regulation
FDA requirements remain central to peptide prescribing and compounding. Act 374 does not replace those requirements. Its licensing board limits apply within the federal pathways referenced in the law.
Key compliance areas include the following:
- 503A compounding under 21 U.S.C. § 353a, including federal limits on bulk drug substances used in compounded preparations.
- 503B outsourcing under 21 U.S.C. § 353b, which applies to FDA-registered outsourcing facilities that meet applicable federal requirements.
- State professional rules governing prescriptive authority, pharmacy practice, and individual licensee activity.
Federal and state authorities have addressed products sold or prescribed outside established pathways. A recent federal case involved imported peptide and GLP-1 products distributed as unapproved drugs in Michigan. State boards have also addressed peptide use directly. In May 2026, the Alabama Board of Medical Examiners issued a notice concerning research-grade and non-FDA-approved peptides, including limits that apply to certain licensed prescribers.
The FDA is also evaluating peptide-related substances through the 503A process. In July 2026, its Pharmacy Compounding Advisory Committee reviewed seven peptide-related bulk drug substances for possible inclusion on the 503A Bulks List. Those recommendations remain advisory pending FDA action. For Med Spa operators and providers offering peptide services, Act 374 limits certain licensing board prohibitions while existing FDA, pharmacy, and professional requirements continue to apply.
Louisiana Act 374 limits certain licensing board restrictions while existing federal peptide requirements remain in effect.
Practical Implications for Louisiana Med Spa Operators and Providers of Peptide Therapies
- Verify sourcing and compounding requirements for GLP-1 medications and other peptides, including applicable 503A or 503B pathway compliance.
- Confirm that providers prescribing peptides hold the required Louisiana prescriptive authority.
- Review pharmacy and supplier documentation for compounded peptides.
- Distinguish qualifying peptide sources from research-grade or otherwise noncompliant channels.
- Monitor FDA and Louisiana board updates that may affect peptide prescribing or compounding.
What to Watch Next
Future Louisiana licensing board guidance or enforcement may provide additional information on how Act 374 is applied. Existing FDA requirements for 503A and 503B compounding remain in effect. Additional state or federal action involving peptide prescribing, compounding, or dispensing may further clarify applicable requirements.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “Baton Rouge Capitol Building” by Yousef Abdul-Husain, via Wikimedia Commons, licensed under CC BY-SA 4.0.
